DAS inhibits Src family kinases (SFKs) via binding to the ATP-binding site, thus inhibiting Src phosphorylation at critical tyrosine residues and decreasing its activation and function in cancer progression signaling pathways. The gene discussed is SRC; the disease is cancer.